StocktoriaUniverse Pharmaceuticals INC UPC
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
3/9
Piotroski F — financial health
7.37
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | $17.9B | $23.0B | $32.3B | $40.1M | $48.0M |
| Gross profit | $6.3B | $6.1B | $10.3B | $21.9M | $25.3M |
| Operating income | -$2.9B | -$8.0B | -$4.0B | -$7.0M | $13.6M |
| Net income | -$3.7B | -$8.7B | -$6.6B | -$7.9M | $11.3M |
| Operating cash flow | -$5.1B | -$9.5B | $1.1B | -$1.3M | -$2.1M |
| Free cash flow | -$5.3B | -$9.7B | $1.1B | -$1.4M | -$2.5M |
| Total assets | $69.3B | $68.0B | $41.7M | $59.5M | $70.1M |
| Total liabilities | $13.2B | $22.5B | $13.8M | — | — |
| Shareholders' equity | $56.1B | $45.5B | $28.0B | $35.3B | $47.0M |
| Ratios | |||||
| Gross margin | 35.3% | 26.4% | 31.9% | 54.5% | 52.8% |
| Operating margin | -16.3% | -34.8% | -12.3% | -17.5% | 28.3% |
| Net margin | -20.6% | -37.9% | -20.4% | -19.7% | 23.6% |
| FCF margin | -29.8% | -42.2% | 3.3% | -3.5% | -5.2% |
| Return on assets | -5.3% | -12.8% | -15772.6% | -13.3% | 16.1% |
| Return on equity | -6.5% | -19.2% | -23.5% | -0.0% | 24.1% |
| Current ratio | 4.07 | 2.54 | 1.84 | 3.17 | 4.50 |
| Revenue growth | -22.4% | -28.7% | 80383.8% | -16.3% | 56.3% |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 7.37 (safe)
- Working capital / assets 0.583
- Retained earnings / assets -0.2
- EBIT / assets -0.042
- Equity / liabilities 4.261
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001809616 · as of 2025-09-30. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.